These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23931952)

  • 1. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
    Jenner P
    Neurol Clin; 2013 Aug; 31(3 Suppl):S17-35. PubMed ID: 23931952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of the rotigotine transdermal patch: a historical perspective.
    Waters C
    Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
    Lyons KE
    Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.
    Steiger M
    Eur J Neurol; 2008 Jan; 15(1):6-15. PubMed ID: 18042245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
    Eskow Jaunarajs KL; Standaert DG; Viegas TX; Bentley MD; Fang Z; Dizman B; Yoon K; Weimer R; Ravenscroft P; Johnston TH; Hill MP; Brotchie JM; Moreadith RW
    Mov Disord; 2013 Oct; 28(12):1675-82. PubMed ID: 24014074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
    LeWitt PA; Lyons KE; Pahwa R;
    Neurology; 2007 Apr; 68(16):1262-7. PubMed ID: 17438216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies with transdermal rotigotine in early Parkinson's disease.
    Poewe W; Luessi F
    Neurology; 2005 Jul; 65(2 Suppl 1):S11-4. PubMed ID: 16030290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.